Prostate Knowledge Archive

Approval by the FDA of a new drug combination for treatment of advanced prostate cancer fills a need and offers new hope to men whose cancer has progressed and who have already tried other therapies.

Guidelines recommend against routine prostate-specific antigen (PSA) testing in men ages 70 and older. Still, two 2023 studies found that men in this age group are having too many PSA tests.

Prostate cancer is generally viewed as a disease of older men, yet about 10% of new diagnoses occur in men age 55 or younger. Biological differences partially explain the discrepancy, but socioeconomic factors also play an important role.

Men who are diagnosed with certain types of prostate cancer often choose active surveillance, which allows them to delay the need for aggressive treatment. The results of a long-term study affirm that this approach is a valid option for managing the disease.

Men with low-risk prostate cancer continue to choose active surveillance as their course of action, meaning they monitor their cancer and don’t seek treatment unless it becomes worse. While this wait-and-see approach may appear passive in nature, it’s an opportunity for men to take charge of their health and make lifestyle changes that could improve their cancer outcome and offer protection against other health risks, like heart disease.

The increasing size and visibility of the transgender population has implications for public health. Hormone treatment given to transgender women lowers the overall risk of prostate cancer, but the risk of a trans woman developing the disease is not zero.

Doctors used to recommend treating all men with prostate cancer; now they are likely to advise active surveillance for lower-risk cancers. But some men require closer monitoring — so how do they determine which ones?

In some men who have prostate cancer surgery the cancer never returns, while in others it does. A new type of imaging technology indicates the presence of prostate tumors, and researchers wanted to know if this could be used to predict cancer recurrence after treatment.

This year, results from a review of literature on plant-based diets and prostate cancer risk concluded that apart from having advantages for cardiovascular health, quality of life, and environmental benefits, plant-based diets have the potential to improve prostate cancer outcomes.

Hormonal therapy is a cornerstone of prostate cancer treatment, but it has burdensome side effects. Doctors and patients alike are highly motivated to use this therapy only for as long as necessary. But how long is long enough? A recent study provides needed clarity.